https://ir.sellaslifesciences.com/generated by Q4Sat, 17 Oct 2026 18:15:02 -0400Copyright Q4 Inc. All rights reserved.24c2682d-0f2c-46d9-b20f-2ce66ba83404https://ir.sellaslifesciences.com/news/News-Details/2026/SELLAS-Life-Sciences-Presents-Preclinical-Data-Demonstrating-SLS009-Activity-in-Pancreatic-Cancer-Models-at-the-2026-AACR-Conference-on-Pancreatic-Cancer/default.aspxFri, 25 Sep 2026 13:00:00 -04006465a667-c3a4-49d5-a916-35e0bb2c908fhttps://ir.sellaslifesciences.com/news/News-Details/2026/SELLAS-Life-Sciences-to-Present-Preclinical-Data-on-SLS009-in-Pancreatic-Ductal-Adenocarcinoma-at-the-2026-AACR-Conference-on-Pancreatic-Cancer/default.aspxWed, 02 Sep 2026 08:30:00 -0400a3e18b00-1898-4399-9fd1-5ecd0fa1f2cahttps://ir.sellaslifesciences.com/news/News-Details/2026/SELLAS-Life-Sciences-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Corporate-Update/default.aspxTue, 11 Aug 2026 16:05:00 -040043fdbccf-f50a-49d3-8568-6b3ff7360fd9https://ir.sellaslifesciences.com/news/News-Details/2026/SELLAS-Life-Sciences-to-Participate-in-Upcoming-Investor-Conferences/default.aspxThu, 14 May 2026 08:00:00 -0400a69dcaa1-ac29-44ee-912d-88e7f3591bc7https://ir.sellaslifesciences.com/news/News-Details/2026/SELLAS-Life-Sciences-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update/default.aspxTue, 12 May 2026 16:05:00 -040031d34482-20eb-4b21-8a8b-d96fddcd10b2https://ir.sellaslifesciences.com/news/News-Details/2026/SELLAS-Life-Sciences-Reports-Full-Year-2025-Financial-Results-and-Provides-Corporate-Update/default.aspxThu, 19 Mar 2026 16:05:00 -0400753edc39-a5a0-47da-8c33-46a496b096b7https://ir.sellaslifesciences.com/news/News-Details/2026/SELLAS-Life-Sciences-to-Present-Preclinical-Data-Highlighting-Potent-Activity-of-SLS009-in-AML-at-the-2026-AACR-Conference/default.aspxTue, 17 Mar 2026 16:30:00 -0400579c5a39-a003-4c09-ae21-a9366e0d4c96https://ir.sellaslifesciences.com/news/News-Details/2026/SELLAS-Life-Sciences-Announces-Enrollment-of-First-Patient-in-Newly-Diagnosed-First-Line-AML-Trial-of-SLS009/default.aspxThu, 12 Mar 2026 08:35:00 -04008812c211-466c-4619-9483-0e9ba568db2bhttps://ir.sellaslifesciences.com/news/News-Details/2026/SELLAS-Life-Sciences-Enters-Agreement-with-IMPACT-AML-to-Expand-SLS009-Clinical-Program-into-Europe/default.aspxWed, 14 Jan 2026 08:30:00 -05009622306e-aa9c-4953-be9a-f5b703df1afchttps://ir.sellaslifesciences.com/news/News-Details/2025/SELLAS-Life-Sciences-Provides-Update-on-Pivotal-Phase-3-REGAL-Trial-of-Galinpepimut-S-GPS-in-Acute-Myeloid-Leukemia-AML/default.aspxMon, 29 Dec 2025 08:35:00 -0500